BioWorld

Feb. 22, 2008

View Archived Issues

Genmab Pays $240M for PDL's Antibody Manufacturing Facility

Strengthening its position as a major antibody player, Genmab A/S said it is securing its own manufacturing capability in a deal to acquire troubled PDL BioPharma Inc.'s Brooklyn, Minn., facility for $240 million. (BioWorld Today) Read More

Affomix Closes $7M Series A for Automatic Antibody Effort

Read More

Glutamate Newest Transmitter Found to Influence Platelets

Read More

NewCo News: With Fresh Eggs, Stemagen Inc. Manages Fresh Cloning Start

Read More

Other News To Note

Read More

Clinic Roundup

Read More